COVID-19 – Biofortis’ Continuity Plan

Posted On 2020-11-04

Biofortis, covid19

UPDATE – November 4th of 2020

The French President has announced a 30-day lockdown requiring the majority of residents to remain at home. Please know that our two Biofortis clinical centers (Paris and Nantes) will remain open during this time in accordance with the rules established for this lockdown. 

And, our team is currently working to identify solutions which allow us to reduce the number of in‐person visits to the clinic while also maintaining the integrity of your trial. Our priorities will be to protect the safety of study subjects as well as to ensure the scientific relevance and quality of each study.

The central lab will also remain open during this time to ensure ongoing specimen management, kit logistics and sample analysis.

Meanwhile, our Biofortis team is working diligently, remotely or on site, in order to guarantee the turnaround time of your project and to minimize the impact of this current crisis on your study activities.

Our entire Biofortis team remains at your disposal should you have any questions.

We sincerely hope that you and your family will not suffer from this virus and I am looking forward to seeing you soon.

In addition of our standard services (clinical trial, central lab, microbiome, data analytics) and according the roots of our company, Biofortis supports the french COVID-19 testing program with two new services in response to the current health challenges: 

  • in vitro Diagnostics / as part of the national effort to deploy diagnostic tests, Biofortis has received an agreement to perform the detection of the SARS-CoV-2 genome by RT PCR

  • SARS-CoV-2 Surface PCR testing / in support of MXNS laboratories by opening access to some of our facilities and equipment

Detection of the SARS-CoV-2 genome by RT PCR

We come in support of the medical laboratory to offer our services in order to respond to a public health issue. Indeed, as a central lab for clinical studies, we are used to working on germs, including some dangerous bacteria. Thus, we already have completely secure procedures and premises in place. This type of public health mission therefore makes sense for Biofortis. Today, before putting these analyses into practice, several validations have to be carried out (analytical and organisational in particular). To ensure the safety of our employees and volunteers, Biofortis will receive only samples in its laboratory to conduct the analytical part of the diagnosis: the 1st stage of nasopharyngeal sampling and the last stage of biological validation will be carried out by medical laboratories. 

Here is a link towards an article written by Thomas Carton one month ago, about the detection method of coronavirus if you want to know more: About Coronavirus detection methods

Don’t hesitate to contact us for more information:

covid19 biofortis

Related Posts

[NEWS] Welcome aboard Morgan and Fanny!

[NEWS] Welcome aboard Morgan and Fanny!

We are pleased to welcome Morgan Cabigliera, as Head of the Sales & Marketing Business Unit and Fanny Doistau, as Clinical Business Unit Director, as part of the Biofortis team.  Morgan has a...